RxDoctor Payments Data

Jamie Szymarek

Nurse Practitioner · Kernersville, NCNPI 1619435724

Payments from drug & device makers

$2,507in general payments, 2019–2025

Across 104 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$915
  • Novo Nordisk$334
  • Welch Allyn$263
  • AbbVie$258
  • Baxter Healthcare$256
  • Amgen$87
  • plus $393 from 14 others

What the payments were for

  • Food & beverage$2,02881%
  • Other$47919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,507 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,887
Medicare patients
21
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$63,075
MounjaroTirzepatide45$47,282
WegovySemaglutide18$23,372
Memantine Hcl ErMemantine Hcl11$2,584
Ursodiol17$1,106
Omeprazole56$810
Topiramate101$403
Ondansetron OdtOndansetron21$363
Naltrexone Hcl12$319
Pravastatin Sodium14$299
Donepezil Hcl12$284
Famotidine12$194
Bupropion XlBupropion Hcl14$105
Metformin Hcl12$51
Metoclopramide Hcl14$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$334$86,44875 claims
Lilly USA, LLCMounjaro$62$47,28245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Kernersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →